GlassScriptPhysician profile
Changxin Li
NPI 1114958899
$3,241.87
in general payments reported to CMS, 2019-2025
27 companies · $27.52 in 2025
The $27.52 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,277 · 2020: $179 · 2021: $62.72 · 2022: $425 · 2023: $1,060 · 2024: $211 · 2025: $27.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,256 · Education: $42.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.59 |
| Education | $42.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $427.26 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $378.71 | 2019-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.75 | 2019-2023 | Jardiance, Synjardy |
| Pfizer INC. | $293.64 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $287.20 | 2019-2024 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $274.00 | 2022-2023 | |
| Glaxosmithkline, LLC. | $267.66 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $160.10 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $112.66 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $82.51 | 2019-2023 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $80.51 | 2023-2024 | Rexulti |
| Astellas Pharma US INC | $73.27 | 2019-2024 | Myrbetriq, Veozah |
| Lilly USA, LLC | $65.46 | 2019-2024 | Jardiance, Zepbound, Mounjaro |
| Sanofi-Aventis U.S. LLC | $62.90 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.74 | 2023-2025 | Eohilia, Gattex |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $40.68 | 2023 | Cologuard Collection Kit |
| Dexcom, INC. | $40.54 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.55 | 2023-2024 | |
| Medtronic Minimed, INC. | $34.46 | 2019 | |
| Alexion Pharmaceuticals, INC. | $32.87 | 2022 | |
| Merck Sharp & Dohme LLC | $32.61 | 2019 | |
| Mylan Specialty L.P. | $27.54 | 2020-2022 | |
| Allergan, INC. | $18.55 | 2019 | |
| Daiichi Sankyo INC. | $17.77 | 2023 | Injectafer |
| Electromed, INC. | $15.59 | 2022 | |
| Abbott Laboratories | $14.27 | 2019 | |
| Strongbridge US INC. | $14.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Changxin Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.